Shannon R. Morris
Chief Medical OfficerDr. Shannon R. Morris, M.D., Ph.D., serves as Chief Medical Officer at Erasca, Inc. since April 2023 and served as its Senior Vice President of Clinical Development since joining in May 2022 until April 2023. She joined Erasca from Oncology, Inc., where she was Vice President, Head of clinical development from September 2020 to March 2022. Prior to joining Istari, she was Vice President of Clinical Development at G1 Therapeutics, Inc. since April 2017 until September 2020 and its Product Team Leader – trilaciclib. Dr. Morris was responsible for the clinical development of trilaciclib. Dr. Morris served as Senior Clinical Director of Oncology at MedImmune from October 2014 to March 2017. Dr. Morris was a key contributor to the first Biologics License Application (BLA) submission and the U.S. Food and Drug Administration approval of ImfinziTM, an immunotherapy product for bladder cancer. Prior to MedImmune, Dr. Morris held roles of increasing responsibility at GSK plc (formerly known as GlaxoSmithKline plc), where her efforts focused on the early phase development of small molecule inhibitors of AKT, PI3K, and MEK, including the approved MEK inhibitor Mekinist. She has experience in the life sciences with a focus in oncology. Earlier in her career, Dr. Morris was an attending oncologist at the University of North Carolina, Chapel Hill. Dr. Morris earned her MD and PhD degrees in molecular virology from Case Western Reserve University and her BS in biological sciences from Stanford University. Dr. Morris completed her internal medicine residency and oncology fellowship at the University of North Carolina.
Positions
- Company NameErasca, Inc.Stock CodeERASPositionChief Medical OfficerColleagues
- JEJonathan E. LimCo-Founder, Chairman & CEO
- DMDavid M. ChackoCFO & Chief Business Officer
- MDMichael D. VarneyChairman of Research & Development, Scientific Advisory Board Member and Director
- ATAlison Tjosvold MilhousSenior Vice President of Accounting
- JAJames A. BristolLead Independent Director
- AWAlexander Whitman CasdinIndependent Director
- VHValerie Harding-StartIndependent Director
